JPMorgan analysts recommend Bristol Myers Squibb as a top biopharma pick.

A financial institution warning about the future of bitcoin and cryptocurrencies.

JPMorgan upgraded the stock to overweight from neutral.

Provided a warning about U.S.-China risks and stock recommendations.

Used data to highlight the disconnect between individual traders and market sentiment.

Provided recent data indicating significant inflows into gold ETFs.

Shares shed roughly 2% as part of a decline due to recession concerns.

Traders from JPMorgan commented on the market's movements and investor behavior.

Retail analyst discussed consumer resilience on CNBC.